NCT07182435View on ClinicalTrials.gov

Exploratory Clinical Study of Personalized mRNA Tumor Vaccine RH125 in Patients With Advanced Solid Tumors

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Solid Tumor Malignancies
Interventions
BIOLOGICAL

personalized neoantigen mRNA tumor vaccine

RH125 is a personalized neoantigen mRNA tumor vaccine which is constructed based on the results of patients' neoantigen sequencing.

Trial Locations (1)

518100

Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen

All Listed Sponsors
lead

Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center

OTHER

NCT07182435 - Exploratory Clinical Study of Personalized mRNA Tumor Vaccine RH125 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter